What is the recommended cephalexin dosing for acute bacterial parotitis in adults and children, and how should the dose be adjusted for renal impairment or cephalosporin allergy?

Cephalexin Dosing for Parotid Infection

For acute bacterial parotitis, use cephalexin 500 mg four times daily (QID) in adults and 25-50 mg/kg/day divided into 4 doses in children, treating it as a skin and soft tissue infection (SSTI) caused by methicillin-susceptible Staphylococcus aureus (MSSA).

Rationale and Dosing Details

Parotid infections are typically caused by MSSA and should be approached as SSTIs. The FDA-approved dosing for cephalexin provides clear guidance 1:

Adult Dosing

• Standard dose: 250 mg every 6 hours (QID)
• For more severe infections or less susceptible organisms: 500 mg every 6 hours (QID) or 500 mg every 12 hours (BID) for milder cases
• Maximum daily dose: 4 grams per day
• The IDSA SSTI guidelines support cephalexin 500 mg QID for MSSA infections 2

Pediatric Dosing

• Standard dose: 25-50 mg/kg/day divided into 3-4 doses 1
• For severe infections: The dose may be doubled 1
• Recent pharmacokinetic data suggests that for MSSA with MIC ≤2 mg/L, twice-daily dosing of 22-45 mg/kg or three-times-daily dosing of 15-25 mg/kg achieves adequate drug levels 3
• However, FDA labeling recommends QID dosing, which remains the gold standard 1

Renal Dose Adjustment

Patients with creatinine clearance <30 mL/min require dose reduction proportional to their reduced renal function 4. While specific adjustment tables are not provided in the FDA label, general principles apply:

• Monitor serum creatinine or calculate creatinine clearance
• Reduce dose proportionally to degree of renal impairment
• Consider extending dosing intervals rather than reducing individual doses

Management of Penicillin Allergy

This is a critical consideration since cephalexin shares structural similarities with penicillins:

Risk Stratification

Cephalexin has higher cross-reactivity with penicillins than other cephalosporins because it shares the R1 side chain with aminopenicillins. The 2022 drug allergy practice parameter indicates cross-reactivity rates of 16.45% (95% CI: 11.07-23.75) for aminocephalosporins like cephalexin in patients with proven penicillin allergy 5.

Decision Algorithm for Penicillin-Allergic Patients

If history of anaphylaxis, angioedema, or severe IgE-mediated reaction to penicillin:

• Avoid cephalexin - use clindamycin 300-400 mg QID (adults) or 20 mg/kg/day in 3 divided doses (children) instead 2

If history of non-severe reaction (e.g., rash without systemic symptoms):

• Cephalexin can be used with caution 6, 7
• The actual cross-reactivity risk is lower than historically quoted, but cephalexin specifically carries higher risk than cephalosporins like cefazolin 5
• Consider using an alternative cephalosporin with dissimilar side chains (e.g., cefazolin has only 0.8% cross-reactivity in confirmed penicillin allergy) 5

Never use cephalexin in patients with:

• Stevens-Johnson syndrome
• Toxic epidermal necrolysis
• Acute interstitial nephritis
• Drug-induced liver injury from penicillins 5

Alternative Antibiotic

If cephalexin is contraindicated, clindamycin is the preferred alternative for MSSA parotitis:

• Adults: 300-450 mg QID orally 2
• Children: 30-40 mg/kg/day in 3 divided doses orally 2

Treatment Duration

While not specifically addressed for parotitis in the evidence, treat for 7-10 days based on clinical response, consistent with SSTI treatment principles 1.

Common Pitfalls

• Don't assume all cephalosporins have equal cross-reactivity - cephalexin specifically has higher risk than cefazolin or third-generation agents 5
• Don't use BID dosing for serious infections - while emerging data supports less frequent dosing for bone infections 3, 8, FDA labeling and IDSA guidelines recommend QID dosing for reliability 2, 1
• Don't forget renal adjustment - cephalexin is renally cleared and accumulates in renal impairment 4